Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us
Global And Market PharmaPoint Asthma Drug Report Forecast and Analysis to 2023
Summary
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
To Browse a Full Report with Toc: http://researchmoz.us/pharmapoint-asthma-global-drug-forecast-and-market-analysis-to-2023-report.html
Key Findings
- The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers.
- The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol)and Symbicort (budesonide/formoterol fumarate).
- Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma.
- The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.
Scope
- Overview of asthma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the asthma therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Table 25: Country Profile, Asthma Management - Italy 110
Table 26: Country Profile, Asthma Management - UK 112
Table 27: Country Profile, Asthma Management - Japan 114
Table 28: Country Profile, Asthma Management - Australia 115
Table 29: Leading Treatments for Asthma, 2014 121
Table 30: Product Profile - Flovent 123
Table 31: Efficacy - Flovent Diskus Versus Placebo 124
Table 32: Adverse Events Related to Flovent Diskus 125
Table 33: Flovent SWOT Analysis, 2014 125
Table 35: Product Profile - Pulmicort 128
Table 36: Pulmicort-Associated Adverse Events 130
Table 37: Pulmicort SWOT Analysis, 2014 131
Table 38: Global Sales Forecast ($) for Pulmicort, 2013-2023 132
Table 39: Summary of Other Marketed ICSs for Asthma Treatment, 2014 133
Table 40: Product Profile - Advair 137
Table 41: Efficacy - Advair Diskus Versus Its Individual Components 138
Table 42: Advair, Frequency of Drug-Related Adverse Events 139
Table 43: Advair SWOT Analysis, 2014 139
Table 44: Global Sales Forecast ($) for Advair, 2013-2023 141
Table 45: Product Profile - Symbicort 142
Table 46: Efficacy - Symbicort Versus Its Individual Components 143
Table 47: Symbicort, Frequency of Drug-Related Adverse Events 144
Table 48: Symbicort SWOT Analysis, 2014 144
Table 49: Global Sales Forecast ($) for Symbicort, 2013-2023 146
Table 50: Product Profile - Breo Ellipta 147
Table 51: Efficacy - Breo Ellipta Versus Flovent 148
Table 52: Safety - Breo Ellipta Versus Flovent 148
Table 53: Breo Ellipta SWOT Analysis, 2014 149
Table 54: Global Sales Forecast ($) for Breo Ellipta, 2013-2023 150
1.2 List of Figures
Figure 1: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011 47
Figure 2: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023 79
Figure 3: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), 2013 82
Figure 4: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, N (Millions), 2013 84
Figure 5: 10MM, Age-Standardized Lifetime Prevalence of Asthma, All Ages, Men and Women, %, 2013 85
Figure 6: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Millions), 2013 88
To Browse a Full Report with Toc: http://researchmoz.us/pharmapoint-asthma-global-drug-forecast-and-market-analysis-to-2023-report.html
All Reports of this Category Here: http://researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
Global And Market PharmaPoint Asthma Drug Report Forecast and Analysis to 2023
Summary
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
To Browse a Full Report with Toc: http://researchmoz.us/pharmapoint-asthma-global-drug-forecast-and-market-analysis-to-2023-report.html
Key Findings
- The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers.
- The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol)and Symbicort (budesonide/formoterol fumarate).
- Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma.
- The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.
Scope
- Overview of asthma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the asthma therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Table 25: Country Profile, Asthma Management - Italy 110
Table 26: Country Profile, Asthma Management - UK 112
Table 27: Country Profile, Asthma Management - Japan 114
Table 28: Country Profile, Asthma Management - Australia 115
Table 29: Leading Treatments for Asthma, 2014 121
Table 30: Product Profile - Flovent 123
Table 31: Efficacy - Flovent Diskus Versus Placebo 124
Table 32: Adverse Events Related to Flovent Diskus 125
Table 33: Flovent SWOT Analysis, 2014 125
Table 35: Product Profile - Pulmicort 128
Table 36: Pulmicort-Associated Adverse Events 130
Table 37: Pulmicort SWOT Analysis, 2014 131
Table 38: Global Sales Forecast ($) for Pulmicort, 2013-2023 132
Table 39: Summary of Other Marketed ICSs for Asthma Treatment, 2014 133
Table 40: Product Profile - Advair 137
Table 41: Efficacy - Advair Diskus Versus Its Individual Components 138
Table 42: Advair, Frequency of Drug-Related Adverse Events 139
Table 43: Advair SWOT Analysis, 2014 139
Table 44: Global Sales Forecast ($) for Advair, 2013-2023 141
Table 45: Product Profile - Symbicort 142
Table 46: Efficacy - Symbicort Versus Its Individual Components 143
Table 47: Symbicort, Frequency of Drug-Related Adverse Events 144
Table 48: Symbicort SWOT Analysis, 2014 144
Table 49: Global Sales Forecast ($) for Symbicort, 2013-2023 146
Table 50: Product Profile - Breo Ellipta 147
Table 51: Efficacy - Breo Ellipta Versus Flovent 148
Table 52: Safety - Breo Ellipta Versus Flovent 148
Table 53: Breo Ellipta SWOT Analysis, 2014 149
Table 54: Global Sales Forecast ($) for Breo Ellipta, 2013-2023 150
1.2 List of Figures
Figure 1: Lifetime Prevalence (%) of Asthma by Race in the US, All Ages, Both Sexes, 2001-2011 47
Figure 2: 10MM, Lifetime Prevalent Cases of Asthma, All Ages, Men and Women, N (Millions), 2013-2023 79
Figure 3: 10MM, Lifetime Prevalent Cases of Asthma, by Age, N (Millions), 2013 82
Figure 4: All Markets, Lifetime Prevalent Cases of Asthma, by Sex, N (Millions), 2013 84
Figure 5: 10MM, Age-Standardized Lifetime Prevalence of Asthma, All Ages, Men and Women, %, 2013 85
Figure 6: 10MM, Lifetime Prevalent Cases of Asthma by Severity, All Ages, Men and Women, N (Millions), 2013 88
To Browse a Full Report with Toc: http://researchmoz.us/pharmapoint-asthma-global-drug-forecast-and-market-analysis-to-2023-report.html
All Reports of this Category Here: http://researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
No comments:
Post a Comment